There are 2 clinical trials

Clinical Trials

1 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study

This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.

NCT00515216 Stomach Neoplasms Esophageal Neoplasms Drug: 5-fluorouracil Drug: Oxaliplatin Drug: Leucovorin

MeSH:Stomach Neoplasms Esophageal Neoplasms Neoplasms

HPO:Esophageal neoplasm Neoplasm Neoplasm of the stomach

This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had a partial response.. Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response).

This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had stable disease.. Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease).

2 Randomized Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

This randomized phase II trial studies the side effects and how well melphalan hydrochloride works in treating patients with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as melphalan hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT03328936 Hematopoietic Cell Transplantation Recipient Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Other: Laboratory Biomarker Analysis Drug: Melphalan Hydrochloride Drug: Melphalan Hydrochloride Other: Pharmacological Study

MeSH:Multiple Myeloma Neoplasms, Plasma Cell

HPO:Multiple myeloma

Will determine the parameter accuracy and precision of the newly integrated PK/PD model for absolute neutrophil count, mucositis, tachyarrhythmias, and disease progression.. XRCC1 rs25487 and XRCC3 rs861529 variant alleles.

Will use Cox survival analysis, measure progression free survival of patients with XRCC1 rs25487 and XRCC3 rs861529 variant alleles compared to wild type.. Inclusion Criteria: - Patient must have relapsed or refractory myeloma that fits or did fit IMWG diagnostic criteria for multiple myeloma; patients with AL amyloidosis and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) are excluded; measurable disease is not required - Patient undergoing autologous transplant as part of first line therapy - All races and ethnic groups are eligible for this study - Patients must also have an adequate autologous graft as defined as a cryopreserved peripheral blood stem cell (PBSC) graft containing > 2 x 10^6 CD34+ cells/kg patient weight - Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma are eligible - Absolute neutrophil count (ANC) > 1000/uL - Platelet count > 50,000 - Transfusion independent - Total bilirubin < 1.5 mg/dL - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal - Left ventricular ejection fraction >= 40% - Carbon monoxide diffusing capability (DLCO) > 50% predicted - Forced expiratory volume in 1 second (FEV1) > 50% predicted - Forced vital capacity (FVC) > 50% predicted - Ability to understand and willingness to sign a written informed consent document - Females of childbearing potential (FCBP) must not be pregnant as per institutional standard; if no institutional standard exists, then patients must have a negative serum or urine pregnancy test prior to transplant; a female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Exclusion Criteria: - Patients who are receiving any other anti-myeloma investigational agents - Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the preceding 6 months, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study; breastfeeding should be discontinued - Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to < 1 year, or confound data interpretation - Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug Inclusion Criteria: - Patient must have relapsed or refractory myeloma that fits or did fit IMWG diagnostic criteria for multiple myeloma; patients with AL amyloidosis and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) are excluded; measurable disease is not required - Patient undergoing autologous transplant as part of first line therapy - All races and ethnic groups are eligible for this study - Patients must also have an adequate autologous graft as defined as a cryopreserved peripheral blood stem cell (PBSC) graft containing > 2 x 10^6 CD34+ cells/kg patient weight - Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma are eligible - Absolute neutrophil count (ANC) > 1000/uL - Platelet count > 50,000 - Transfusion independent - Total bilirubin < 1.5 mg/dL - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal - Left ventricular ejection fraction >= 40% - Carbon monoxide diffusing capability (DLCO) > 50% predicted - Forced expiratory volume in 1 second (FEV1) > 50% predicted - Forced vital capacity (FVC) > 50% predicted - Ability to understand and willingness to sign a written informed consent document - Females of childbearing potential (FCBP) must not be pregnant as per institutional standard; if no institutional standard exists, then patients must have a negative serum or urine pregnancy test prior to transplant; a female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Exclusion Criteria: - Patients who are receiving any other anti-myeloma investigational agents - Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the preceding 6 months, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study; breastfeeding should be discontinued - Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to < 1 year, or confound data interpretation - Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug Hematopoietic Cell Transplantation Recipient Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Multiple Myeloma Neoplasms, Plasma Cell PRIMARY OBJECTIVES: I. Identify whether targeting approximate (approx.)

V. Measure allele and genotype frequencies of variants, as well as gene expression of XRCC1 rs25487 and XRCC3 rs861529.

HPO Nodes